Predicting Treatment Response in Chronic Hepatitis C
Author Information
Author(s): Martin Lagging, Galia Askarieh, Francesco Negro, Stephanie Bibert, Jonas Söderholm, Johan Westin, Magnus Lindh, Ana Romero, Gabriele Missale, Carlo Ferrari, Avidan U. Neumann, Jean-Michel Pawlotsky, Bart L. Haagmans, Stefan Zeuzem, Pierre-Yves Bochud, Kristoffer Hellstrand, DITTO-HCV Study Group
Primary Institution: Department of Infectious Diseases/Virology, University of Gothenburg, Gothenburg, Sweden
Hypothesis
Can the assessment of IP-10 and IL28B-related SNPs improve predictions of treatment outcomes in chronic hepatitis C patients?
Conclusion
The study found that measuring pretreatment IP-10 levels alongside IL28B SNPs can enhance predictions of treatment response in chronic hepatitis C patients.
Supporting Evidence
- High baseline levels of IP-10 predict a slower decline in HCV RNA.
- Favorable SNP variants are associated with lower baseline IP-10 levels.
- Patients with favorable SNP genotypes had higher baseline viral loads.
- IP-10 levels below 150 pg/mL predict better treatment outcomes.
- The study involved a phase III treatment trial with 253 patients.
- Multivariate analyses showed IP-10 and SNPs independently predict treatment response.
Takeaway
Doctors can better predict how well hepatitis C treatment will work by checking certain genes and a protein level in the blood.
Methodology
The study correlated SNP variants with IP-10 levels and HCV RNA during a phase III treatment trial.
Potential Biases
Potential biases may arise from the multicenter trial design and patient selection criteria.
Limitations
The study focused only on Caucasian patients, which may limit the generalizability of the findings.
Participant Demographics
The study involved 253 Caucasian patients, including 180 men and 90 women.
Statistical Information
P-Value
P<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website